



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

May 15, 2021

To,
The Secretary/Executive Director
BSE Limited
National Stock Exchange of India Limited
New York Stock Exchange, Inc.
NSE-IFSC Limited

Dear Sir/Madam,

Sub: Newspaper advertisement regarding financial results for the quarter and year ended March 31, 2021

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the financial results of the company for the quarter and year ended March 31, 2021 as published in Business Standard and Andhra Prabha on May 15, 2021.

This is for your information and records.

With regards,

Sandeep Poddar
Company Secretary

విషయం

అరోగ్యశ్రీలో ఎందుకు చేర్చడం వల్ల పేపర్ లోని అధ్యక్షుడు ఉత్తమ

బెన్చిమార్కు కరోనా బయటపడటం లేదని, చాలా కంటే వచ్చినా.. నెగిటివ్ చూపిస్తుంది దన్నారు. దారికి ఆర్టిఫీషియల్ ఆర్ చేయించాలని ఆయనకు. రూ. 6 కోట్లు ఖర్చు చేస్తే ఆర్టిఫీషియల్ పరీక్షలు వచ్చు. కరోనాతో తాను ఆసుపత్రికి వెళ్ళితే దాదాపు వరకు ఖర్చయిందని, నేను ఎంపీని కాబట్టి పేదని, అదే సామాన్య ప్రజల పరిస్థితి ఏంటని అంటారు. 104,108 ని నిర్వీర్యం చేశారని ఆయనకు. పేద ప్రజలు ఆరోగ్య బాగాలేక అంటున్నారని భయమేస్తుందన్నారు. ఆక్సిజన్ బెడ్ కావాలంటే 50 వేల వరకు కేసుని వారు. చికిత్సలు జలకు లుకుం యన రం. ఆసుక్విజన్ కులు భుత్వ దా...? యన

6.	ఉక్కిటి వాటా మూలధనం	79.93	79.63	1.81	213.60	67.38
7.	రిజర్వులు (రీవాల్యుయేషన్ రిజర్వులు మినహా) ముందు సంవత్సరపు ఆడిట్ చేసిన బ్యాలెన్స్ షీట్ లో చూపిన విధంగా				1,898.97	1,685.37
8.	ప్రతి వాటా అర్జనలు (రూ.2/- ఒక్కొక్కటి) (కాపాగుతున్న మరియు నిలిపివేసిన కార్యకలాపాల కొరకు)					
	ఎ) బేసిక్ (ఐఎన్ఆర్)	3.50	3.62	0.06	9.62	3.13
	బి) డైల్యూటెడ్ (ఐఎన్ఆర్)	3.50	3.62	0.06	9.62	3.13

గమనిక :
 1. సెబీ (లిస్టింగ్ ఆర్టిగేషన్ మరియు డిస్క్లజర్ ఆవశ్యకతలు) రెగ్యులేషన్స్, 2015 యొక్క రెగ్యులేషన్ 33 క్రింద స్టాక్ ఎక్స్చేంజ్ లో దాఖలైన ముగిసిన త్రైమాసిక మరియు సంవత్సరం యొక్క ఆర్థిక ఫలితాల యొక్క వివరణాత్మక సమానా సారాంశం పైన ఇవ్వబడినది. త్రైమాసిక ఆర్థిక ఫలితాల యొక్క పూర్తి సమానా కంపెనీ వెబ్సైట్ (www.vimta.com) మరియు బిఎస్ఐఐ లిమిటెడ్ వెబ్సైట్ (www.bseindia.com) మరియు నేషనల్ స్టాక్ ఎక్స్చేంజ్ ఆఫ్ ఇండియా లిమిటెడ్ (www.nseindia.com) పై లభించును.
 2. మార్చి 31, 2021లో ముగిసిన త్రైమాసిక మరియు సంవత్సరం కొరకు కంపెనీ యొక్క పైన ఆడిట్ చేసిన ఆర్థిక ఫలితాలు మే 13, 2021 న ఆడిట్ కమిటీ చే సమీక్షించబడినవి మరియు మే 14, 2021 న జరిగిన వారి సమావేశంలో డైరెక్టర్ బోర్డు వారిచే ఆమోదించబడినవి.
 3. ముందు కాలపు సంఖ్యలు అవసరమని భావించిన యెడల రీరూస్ / రీకాస్ట్ / తిరిగి వర్గీకరించబడినవి.
 For and on behalf of the Board of Directors
Vimta Labs Limited
 Harita Vasireddi
 Managing Director
 Place: Hyderabad, INDIA
 Date: May 14, 2021

Dr.Reddy's Extract of audited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and year ended 31 March 2021 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

SI. No.	Particulars	Consolidated			
		Quarter ended 31.03.2021 (Audited)	Quarter ended 31.03.2020 (Audited)	Year ended 31.03.2021 (Audited)	Year ended 31.03.2020 (Audited)
1	Total Revenue from Operations	47,682	44,489	190,475	175,170
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	8,152	7,362	28,835	18,857
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	8,152	7,362	28,835	18,857
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	5,573	7,811	19,516	20,260
5	Total Comprehensive Income for the period	6,365	6,548	24,916	19,610
6	Equity Share Capital	832	831	832	831
7	Reserves (excluding Revaluation Reserve)			175,585	155,157
8	Earnings per share (in Rupees) per Rs. 5/- share				
	Basic	33.61	47.12	117.67	122.22
	Diluted	33.51	47.03	117.34	121.99

SI. No.	Particulars	Standalone			
		Quarter ended 31.03.2021 (Audited)	Quarter ended 31.03.2020 (Audited)	Year ended 31.03.2021 (Audited)	Year ended 31.03.2020 (Audited)
1	Total Revenue from Operations	33,507	28,517	133,491	118,504
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	4,569	4,441	30,562	27,758
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	4,569	4,441	30,562	27,758
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	3,115	5,028	21,864	29,377
5	Total Comprehensive Income for the period	3,053	4,777	22,405	28,941
6	Equity Share Capital	832	831	832	831
7	Reserves (excluding Revaluation Reserve)			169,005	151,088
8	Earnings per share (in Rupees) per Rs. 5/- share				
	Basic	18.78	30.34	131.84	177.23
	Diluted	18.73	30.28	131.46	176.88

Notes:
 1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.
 2 The audited results have been reviewed by the Audit Committee of the Board at their meeting held on 13 May 2021 and approved by the Board of Directors of the Company at their meeting held on 14 May 2021.

By order of the Board
 For Dr. Reddy's Laboratories Limited
 G V Prasad
 Co-Chairman & Managing Director
 Place : Hyderabad
 Date : 14 May 2021
Dr. REDDY'S LABORATORIES LIMITED
 Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
 CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
 email: shares@drreddys.com, website: www.drreddys.com

Notes :

- The above financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th May 2021 and have been audited by the Statutory Auditors.
- The above is an extract of the detailed format of the financial results for the quarter and year ended March 31, 2021 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Company's website (www.ginnifilaments.com) and Stock Exchange website (www.nseindia.com).
- The above results are in accordance with the Companies (Indian Accounting Standards) Rules, 2015 as amended time to time and prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- The figures for the quarter ended March 31, 2021 and quarter ended March 31, 2020 are the balancing figures between audited figures for the year ended March 31, 2021 and March 31, 2020 and the unaudited figures of nine months ended December 31, 2020 and December 31, 2019 respectively.
- During the year ended March 31, 2021, the Company has allotted 1,50,00,000 warrants each carrying a right to subscribe to one equity share per warrant, at a price of Rs.12.5 per warrant, aggregating to Rs.1,875 lacs on a preferential basis to group companies. Out of which 85,00,000 equity shares has been allotted at Rs.12.5 per share (including security premium of Rs.2.5 per share) against such warrants during the year on receipt of full consideration amounting to Rs.1,062.50 lacs. An amount equivalent to 25% of 65,00,000 warrant pending conversion amounting to Rs.203.13 lacs has been received during the year and the balance 75% of such warrant shall be payable at the time of allotment of equity shares pursuant to exercise of the options attached to warrants to subscribe equity shares.


For and on behalf of the Board of Directors
Ginni Filaments Limited
Sd/-

Shishir Jaipuria

Chairman and Managing Director

Place : Noida

Date : 14th May 2021

Dr.Reddy's 

Extract of audited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and year ended 31 March 2021 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated			
		Quarter ended	Quarter ended	Year ended	Year ended
		31.03.2021 (Audited)	31.03.2020 (Audited)	31.03.2021 (Audited)	31.03.2020 (Audited)
1	Total Revenue from Operations	47,682	44,489	190,475	175,170
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	8,152	7,362	28,835	18,857
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	8,152	7,362	28,835	18,857
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	5,573	7,811	19,516	20,260
5	Total Comprehensive Income for the period	6,365	6,548	24,916	19,610
6	Equity Share Capital	832	831	832	831
7	Reserves (excluding Revaluation Reserve)			175,585	155,157
8	Earnings per share (in Rupees) per Rs. 5/- share				
	Basic	33.61	47.12	117.67	122.22
	Diluted	33.51	47.03	117.34	121.99

Sl. No.	Particulars	Standalone			
		Quarter ended	Quarter ended	Year ended	Year ended
		31.03.2021 (Audited)	31.03.2020 (Audited)	31.03.2021 (Audited)	31.03.2020 (Audited)
1	Total Revenue from Operations	33,507	28,517	133,491	118,504
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	4,569	4,441	30,562	27,758
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	4,569	4,441	30,562	27,758
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	3,115	5,028	21,864	29,377
5	Total Comprehensive Income for the period	3,053	4,777	22,405	28,941
6	Equity Share Capital	832	831	832	831
7	Reserves (excluding Revaluation Reserve)			169,005	151,088
8	Earnings per share (in Rupees) per Rs. 5/- share				
	Basic	18.78	30.34	131.84	177.23
	Diluted	18.73	30.28	131.46	176.88

Notes:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.
- The audited results have been reviewed by the Audit Committee of the Board at their meeting held on 13 May 2021 and approved by the Board of Directors of the Company at their meeting held on 14 May 2021.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place : Hyderabad
Date : 14 May 2021

G V Prasad
Co-Chairman & Managing Director

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
email: shares@drreddys.com, website: www.drreddys.com